Lornamead
This article was originally published in The Rose Sheet
Executive Summary
UK company aims to build approximately $500 mil. personal care business in North America in the next three to five years, CEO Mike Jatania says, noting segment is now in excess of $100 mil. with the recent acquisition of Finesse and Aqua Net (1"The Rose Sheet" May 8, 2006, p. 6). In the next 60 days, Lornamead will consult with retailers, conduct focus groups and appoint public relations and advertising agencies to develop its marketing program for the brands, according to Jatania. In November, firm will launch new products under Yardley personal care brand, which was acquired from Procter & Gamble last year, exec adds. Company also markets Natural White teeth whitening products and Lypsyl lip balm...
You may also be interested in...
Lornamead
George Russell tapped CEO for company's North American division, following firm's recent acquisition of the Finesse and Aqua Net brands from Unilever, Lornamead Group announces June 7. Reporting to CEO of Lornamead Group Mike Jatania, Russell will oversee company's product development, manufacturing, distribution and marketing activities in North America, Central and South America, firm notes. Among his goals for the division, Russell notes he will guide the company in reinvesting in and reinvigorating the already well-established hair care brands, and will look for opportunities to acquire additional brands. Lornamead recently stated it hopes to build a $500 mil. personal care business in North America in the next three to five years (1"The Rose Sheet" May 15, 2006, In Brief)...
Lornamead Acquires Finesse and Aqua Net From Unilever
UK based personal care company Lornamead is strengthening its North American presence with the acquisition of mass market hair care brands Finesse and Aqua Net from Unilever
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.